Sullivan & Cromwell LLP Logo
  • Home
  • Lawyers
  • Practices
  • Insights
  • About
  • Careers
  • Alumni
  • Twitter icon
  • LinkedIn icon
  •  icon
  • Podcasts icon
© 2025 Sullivan & Cromwell LLP
    • Home
    • Lawyers
    • Practices
    • Insights
    • About
    • Careers
    • Alumni
    Home /  About /  Rankings And Recognitions /  Firm Highlights
    Firm Highlights

    Biohaven’s $11.6 Billion Deal with Pfizer

    • Our Lawyers
    • Related Practices
    May 25, 2022

    Biohaven Pharmaceutical Holding Company, a small innovator with a revolutionary treatment to both treat and prevent migraines called NURTEC® ODT, successfully commercialized its product in the United States and reached a global licensing deal with Pfizer for countries outside the U.S. With its successful product, it made an attractive asset for large pharmaceutical companies looking for new products for their portfolios, but Biohaven is more than a single product company. It also has a pipeline of potential products in development—including potential treatments for obsessive-compulsive disorder and amyotrophic lateral sclerosis—and large pharmaceutical companies aren’t always willing to ascribe value to a company’s pipeline.

    When Pfizer, flush with cash from its COVID-19 vaccine, approached Biohaven about an acquisition earlier this year, an S&C team led by Frank Aquila and Scott Crofton helped Biohaven reach an agreement using a pioneering deal structure. Pfizer will acquire Biohaven for $11.6 billion in cash and then spin off to Biohaven’s shareholders an entity, New Biohaven, that retains the pipeline products. New Biohaven will also be capitalized with $275 million of cash and will have certain rights to receive U.S. royalties from Pfizer on annual net sales of NURTEC® and a related product in excess of $5.25 billion.

    When completed, this complex transaction may be the first time that a U.S.-listed company biopharma company has spun off pipeline assets.

    The complex transaction required the efforts of a multi-disciplinary team, including Davis Wang, the co-head of S&C’s Tax Group; Bob Downes, the co-head of the Capital Markets Group; Nader Mousavi, the co-head of the Intellectual Property and Technology Group: and Matt Friestedt, who leads the Executive Compensation M&A practice.

    Sullivan & Cromwell led all law firm advisers in global M&A deals announced in 2021. The Firm advised on deals totaling $662.5 billion worldwide, representing an 11 percent market share, according to Refinitiv. The Firm also topped the rankings in deals with any U.S. party involved.

    Read More

    Recent Podcasts & Publications

    • S&C Critical Insights – Episode 2: Implications of SEC's Proposed Climate-Related Disclosure Rules
    • S&C Critical Insights – Episode 1: Implications of SEC's Proposed Climate-Related Disclosure Rules
    • Memo: SEC Proposes Sweeping Changes Regulating SPAC Formation and De-SPAC Transactions
    • Memo: FTC and DOJ Announce Joint Review of Merger Guidelines
    Stay Updated

    Subscribe to stay current on S&C Insights.

    Our Lawyers

    Our Lawyers

    Francis J. Aquila Headshot Photo
    Francis J. Aquila
    New York
    +1-212-558-4048
    Email
    vCard
    Scott B. Crofton Headshot Photo
    Scott B. Crofton
    New York
    +1-212-558-4682
    Email
    vCard
    Robert W. Downes Headshot Photo
    Robert W. Downes
    New York
    +1-212-558-4312
    Email
    vCard
    Nader A. Mousavi Headshot Photo
    Nader A. Mousavi
    Palo Alto
    +1-650-461-5600
    Email
    vCard
    Davis J. Wang Headshot Photo
    Davis J. Wang
    New York
    +1-212-558-4000
    Email
    vCard
    Read More

    Related Practices

    • Capital Markets
    • Executive Compensation
    • Healthcare & Life Sciences
    • Intellectual Property & Technology Transactions
    • Mergers & Acquisitions
    • Tax
    Sullivan & Cromwell LLP Logo
    • Twitter icon
    • LinkedIn icon
    • RSS Feed icon
    • Podcasts icon
    • Home
    • Contact Us
    • Information Policy Relating to Cookies
    • Privacy Policy
    • California Privacy Policy
    • Website Notice
    • Attorney Advertising Notice
    © 2025 Sullivan & Cromwell LLP